Abiopharma

GAIN THERAPEUTICS, INC. (GANX)

Symbol	GANX
Name	GAIN THERAPEUTICS, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	4800 MONTGOMERY LANE,SUITE 220, BETHESDA, Maryland, 20814, United States
Telephone	+1 301 500-1556
Fax	—
Email	—
Website	https://www.gaintherapeutics.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001819411
Description	Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements. Additional info from NASDAQ: Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements.

2026-07-17 12:33

Director GOLDSTEIN DOV A MD 🟢 acquired 25.0K shares (1 derivative) of Gain Therapeutics, Inc. (GANX) at $1.68 Transaction Date: Jul 15, 2026 | Filing ID: 084439

2026-07-17 12:32

Director Nicaise Claude 🟢 acquired 25.0K shares (1 derivative) of Gain Therapeutics, Inc. (GANX) at $1.68 Transaction Date: Jul 15, 2026 | Filing ID: 084438

2026-07-17 12:32

Director Islam Khalid 🟢 acquired 25.0K shares (1 derivative) of Gain Therapeutics, Inc. (GANX) at $1.68 Transaction Date: Jul 15, 2026 | Filing ID: 084437

2026-07-17 12:31

Director Melincoff Gwen A 🟢 acquired 25.0K shares (1 derivative) of Gain Therapeutics, Inc. (GANX) at $1.68 Transaction Date: Jul 15, 2026 | Filing ID: 084435

2026-07-17 12:31

Director Riley Jeffrey Scott 🟢 acquired 25.0K shares (1 derivative) of Gain Therapeutics, Inc. (GANX) at $1.68 Transaction Date: Jul 15, 2026 | Filing ID: 084434

2026-07-17 12:30

Director HASLER HANS PETER 🟢 acquired 25.0K shares (1 derivative) of Gain Therapeutics, Inc. (GANX) at $1.68 Transaction Date: Jul 15, 2026 | Filing ID: 084433

2026-07-16 11:53

(99% Neutral) GAIN THERAPEUTICS, INC. (GANX) Announces Clinical Development Update

2026-07-16 11:00

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

2026-07-16 10:59

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

2026-06-29 20:21

(99% Neutral) GAIN THERAPEUTICS, INC. (GANX) Announces Clinical Development Update

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07280299	Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Park…	Phase2	Parkinson Disease	Not_Yet_Recruiting	2026-05-30	2028-06-30	ClinicalTrials.gov
NCT06732180	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Par…	Phase1	Parkinson Disease	Recruiting	2025-02-21	2025-11-30	ClinicalTrials.gov

Total clinical trials: 2

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
GT-02287	Other	Phase PHASE1	Parkinson Disease	RECRUITING	NCT06732180
Placebo	DRUG	Phase PHASE2	Parkinson Disease	NOT_YET_RECRUITING	NCT07280299
High Dose GT-02287	DRUG	Phase PHASE2	Parkinson Disease	NOT_YET_RECRUITING	NCT07280299
Low Dose GT-02287	DRUG	Phase PHASE2	Parkinson Disease	NOT_YET_RECRUITING	NCT07280299
GT-02287	DRUG	Phase PHASE1	Parkinson Disease	RECRUITING	NCT06732180

Total products: 5